Coeptis Therapeutics shares climbed nearly 12% over the past week to close at $16.40, extending the stock's one-month surge past 57%. The move comes as institutional holders continue to build positions while short sellers hold firm — a setup that has the biotech trading with heightened attention ahead of its May 15 earnings event.
Short interest sits at 6.9% of the free float, essentially flat over the past seven days despite the sharp price rally. That stability is notable — bears have not been shaken out. Cost to borrow has eased slightly to 7.8%, down from 8.5% in early April, but borrow utilization remains elevated at 84.6%, well above comfort levels for a stock this size. The 52-week high for utilization was 94%, reached in late March, suggesting shares available to lend have been close to fully tapped. Days to cover stands at 9.8, implying nearly two weeks of average volume would be required to close existing short positions. The ORTEX short score of 71.9 places COEP in the top decile of tracked names — a signal that the setup remains charged even as the stock rallies.
Institutional activity has been concentrated among insiders and smaller funds. Vanguard added nearly 289,000 shares in the first quarter, lifting its stake to 5.5% of shares outstanding. CEO David Mehalick increased his holdings by 200,000 shares as of the February filing, now controlling 5.3% of the company. Geode and State Street have taken smaller positions. The shareholder base remains thin, with just 21 institutional holders on record as of the end of March. Insider buying activity in the public filings extends back to early 2024, with the most recent disclosed trades showing modest purchases by directors and executives at prices well below current levels. Those transactions are now more than two years old and offer limited insight into current sentiment.
Peers in the biotech space have not matched Coeptis' momentum. VIR fell 3.5% over the week, PRQR dropped 22%, and COYA declined 9.6%. Only AVBP posted a gain, rising 2.6%. The divergence suggests COEP is moving on stock-specific factors rather than sector rotation. Historical reactions to earnings have been mixed — the April 2 print triggered a 3.6% one-day gain, while the March event added 1.7%. Five-day moves have ranged from a 19% rally last November to a 1.7% decline in March. The pattern offers no reliable template.
The next earnings call is scheduled for mid-May. With utilization still running near 85% and short interest holding steady through the rally, the question is whether the current price becomes the new range or whether the lack of analyst coverage and thin institutional base leaves the stock vulnerable to reversal. The high short score and elevated borrow metrics keep the setup active, but the peer underperformance and absence of fresh catalyst news suggest the rally may be running on limited fuel.
See the live data behind this article on ORTEX.
Open COEP on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
